Cellular schwannoma

Summary

Cellular schwannoma (MONDO:0002548) is a disease. A subtype of schwannoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	cellular schwannoma
Mondo ID	MONDO:0002548
DOID	DOID:3196
NCIT	C4724
SNOMED CT	404026003
UMLS	C0431124
MedGen	98124
GARD	0023162
Is cancer (heuristic)	no

Also known as: cellular neurilemmoma · cellular neurinoma · cellular schwannoma · CSCHW

Disease family

This is a subtype of schwannoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › peripheral nervous system disorder › peripheral nervous system neoplasm › nerve sheath neoplasm › schwannoma › cellular schwannoma

Related subtypes (9): acoustic neuroma, schwannoma of twelfth cranial nerve, sympathetic neurilemmoma, trigeminal schwannoma, microcystic/reticular schwannoma, melanotic neurilemmoma, plexiform schwannoma, peripheral nerve schwannoma, schwannomatosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.